There's a new proposed rule that unbundles diagnostic radiopharmaceuticals from the current packaged payment system that classifies them as "supplies." The new rule will prevent CMS from overpaying for low-cost diagnostic radiopharmaceuticals and give patients access to a more precise generation of imaging agents. SNMMI will be submitting a comment in support of the CMS rule and is celebrating this win for patients! Learn more below and on our website: https://lnkd.in/dkPjWqXa
Thanks to SNMMI for all your efforts and being part of the amazing coalition that made this possible. I’ve been working with the Society on this for more than a decade and it’s really gratifying to see it realized now, to benefit so many patients in the future.
This is good news and will start to achieve some balance and cost weighting amongst the myriad of supply chain and cost factors with key radioisotopes.
This is fantastic news and will encourage continued scientific innovation in the exciting area of radiopharmaceutical development.
A notícia do SNMMI sobre a nova regra proposta pelo CMS para 2025 no sistema de pagamento prospectivo de pacientes ambulatoriais é uma vitória significativa para a medicina nuclear. A desagregação de radiofármacos diagnósticos permitirá reembolsos separados para radiofármacos com custos diários superiores a $630, facilitando o acesso a procedimentos avançados e precisos de imagem nuclear. Uma notícia fantástica para a medicina nuclear! 🎉 A nova proposta do CMS para 2025 que desagrega os radiofármacos diagnósticos, permitindo reembolsos separados para os de alto custo, é um grande avanço. Acredito que essa mudança proporcionará acesso mais amplo a procedimentos avançados, melhorando significativamente o cuidado ao paciente. 🌟 Essa mudança trará maior precisão e eficácia no tratamento, eliminando barreiras financeiras e promovendo a inovação. 🚀 #MedicinaNuclear #InovaçãoEmSaúde #AcessoUniversal #Teranósticos #BeatCancer #ImagemMolecular
Thank you for your advocacy 🙏
Love this
Amazing news for the patients!
Such great news!!
🙌🏼🙌🏼🙌🏼 professionals, patients, and healthcare systems-let’s be sure to comment and add support!
Radiology Director/Chair, System Radiology at Texas Health Resources
1moWith a cap of $630 for radiopharmaceuticals, that's helpful for most of the bread and butter studies, but what about the bottom line for hospitals when it comes to higher cost doses such as DAT Scan that run thousands of dollars? The hospitals literally lose thousands of dollars on these types of exams.